Springbok Analytics said its MRI-based muscle analysis AI software will be used to assess a new treatment for facioscapulohumeral muscular dystrophy (FSHD).
The software is designed to help researchers understand and identify disease progression of FSHD by providing individual MRI muscle volume and fat fraction metrics in trial participants, the company said. The software will be used in a phase I dose escalation study assessing the safety and tolerability of clenbuterol, which has demonstrated improved strength or function in patients in several small studies, the company said.
There are currently no therapies approved by the U.S. Food and Drug Administration for FSHD, a progressive muscle degeneration disorder primarily affecting the muscles of the face, shoulder blades, and upper arms, Springbok noted.
